uniQure Added to NASDAQ Biotechnology Index

AMSTERDAM, the Netherlands, Dec. 14, 2015 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced that the Company has been added to the NASDAQ Biotechnology Index® (NBI) as part of NBI's annual selection of biotechnology and pharmaceutical companies listed on the NASDAQ Stock Market® that meet NBI's eligibility criteria. uniQure will be added to the NBI effective prior to market open on December 21, 2015.

The NASDAQ Biotechnology Index is a modified market capitalization weighted index that is designed to track the performance of a set of securities listed on The NASDAQ Stock Market® (NASDAQ®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark and is re-ranked annually in December. Additional information on the eligibility criteria and further details about the index are available here: https://indexes.nasdaqomx.com/docs/methodology_NBI.pdf

About uniQure

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with CNS, liver/metabolic and cardiovascular diseases. www.uniQure.com

CONTACT: uniQure: Aicha Diba Investor Relations Direct : +31 20 240 6100 Main: +31 20 566 7394 a.diba@uniQure.com Media inquiries: Gretchen Schweitzer MacDougall Biomedical Communications Direct: +49 172 861 8540 Main: +49 89 2424 3494 or +1 781 235 3060 gschweitzer@macbiocom.comSource: uniQure